U01 Stock Overview
Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Delivra Health Brands Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.012 |
| 52 Week High | CA$0.022 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.33 |
| 1 Month Change | -31.43% |
| 3 Month Change | -31.43% |
| 1 Year Change | 50.00% |
| 3 Year Change | -84.38% |
| 5 Year Change | -97.86% |
| Change since IPO | -96.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| U01 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.5% |
| 1Y | 50.0% | -28.6% | 1.3% |
Price Volatility
| U01 volatility | |
|---|---|
| U01 Average Weekly Movement | 48.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: U01's share price has been volatile over the past 3 months.
Volatility Over Time: U01's weekly volatility has decreased from 168% to 48% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Gord Davey | delivrahealthbrands.com |
Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The company is involved in selling of cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It offers its products under LivRelief, Dream Water, and LivRelief infused brand names.
Delivra Health Brands Inc. Fundamentals Summary
| U01 fundamental statistics | |
|---|---|
| Market cap | €7.47m |
| Earnings (TTM) | -€758.02k |
| Revenue (TTM) | €7.77m |
1.1x
P/S Ratio-11.3x
P/E RatioIs U01 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U01 income statement (TTM) | |
|---|---|
| Revenue | CA$11.39m |
| Cost of Revenue | CA$5.41m |
| Gross Profit | CA$5.99m |
| Other Expenses | CA$7.10m |
| Earnings | -CA$1.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0036 |
| Gross Margin | 52.54% |
| Net Profit Margin | -9.75% |
| Debt/Equity Ratio | 50.8% |
How did U01 perform over the long term?
See historical performance and comparison